MRKR Marker Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1094038 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-30.7%
TTM net income YoY14.8%
TTM EPS YoY58.3%
Revenue 3-yr CAGR1.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-365.9%
Net margin-275.9%
FCF margin—
EBITDA margin—
Returns
ROE-77.0%
ROA-63.3%
ROIC (approx.)—
Asset turnover0.23x
Leverage & solvency
Liabilities / assets20.9%
Debt / equity0.00x
Current ratio4.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-17.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $3.55M | $6.59M | $3.31M | $3.51M | $1.24M |
| R&D expense | $11.80M | $13.47M | $10.42M | $11.97M | $27.79M |
| SG&A expense | $4.18M | $4.24M | $7.48M | $11.34M | $12.92M |
| Operating income | -$12.89M | -$11.12M | -$14.58M | -$19.79M | -$39.48M |
| Pretax income | -$12.18M | -$10.68M | -$14.04M | -$19.78M | — |
| Income tax | -$15,156 | $49,953 | $3,675 | — | — |
| Net income | -$12.16M | -$10.73M | -$8.24M | -$29.93M | -$41.88M |
| EBITDA | — | — | — | -$17.00M | -$37.33M |
| EPS (basic) | -0.79 | -1.19 | -0.94 | -3.58 | -5.47 |
| EPS (diluted) | -0.79 | -1.19 | -0.94 | -3.58 | -5.47 |
| Weighted avg. shares (diluted) | 15.31M | 8.98M | 8.81M | 8.35M | 7.65M |
| Balance sheet | |||||
| Cash & equivalents | $16.07M | $19.19M | $15.11M | $11.78M | $43.50M |
| Current assets | $19.07M | $22.02M | $17.13M | $16.62M | $45.98M |
| PP&E, net | — | — | — | $12.32M | $12.32M |
| Total assets | $19.07M | $22.02M | $17.13M | $34.42M | $68.14M |
| Current liabilities | $2.27M | $3.46M | $3.07M | $7.78M | $12.90M |
| Total liabilities | $2.27M | $3.46M | $3.07M | $14.82M | $24.15M |
| Shareholders' equity | $16.80M | $18.56M | $14.05M | $19.60M | $43.99M |
| Shares outstanding | 16.70M | 10.70M | 8.90M | 8.40M | 8.30M |
| Cash flow statement | |||||
| Operating cash flow | -$12.01M | -$10.91M | -$16.44M | -$26.97M | -$27.28M |
| Investing cash flow | — | — | $18.66M | -$4.95M | -$3.13M |
| Financing cash flow | $9.86M | $14.99M | $1.11M | $202,130 | $52.56M |
| Depreciation & amortization | — | — | — | $2.79M | $2.15M |
| Stock-based compensation | $537,540 | $245,864 | $858,269 | $3.30M | $5.96M |
Free plan shows the latest 5 periods; Pro shows all 26 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.